Can-Fite BioPharma Ltd. (CANF)
AMEX: CANF
· Real-Time Price · USD
0.65
-0.01 (-1.50%)
At close: Aug 19, 2025, 11:46 AM
-1.50% (1D)
| Bid | 0.64 |
| Market Cap | 5.68M |
| Revenue (ttm) | 674K |
| Net Income (ttm) | -7.88M |
| EPS (ttm) | -2.6 |
| PE Ratio (ttm) | -0.25 |
| Forward PE | -23 |
| Analyst | Buy |
| Ask | 0.66 |
| Volume | 42,211 |
| Avg. Volume (20D) | 179,745 |
| Open | 0.65 |
| Previous Close | 0.66 |
| Day's Range | 0.64 - 0.66 |
| 52-Week Range | 0.63 - 3.12 |
| Beta | 0.08 |
About CANF
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CANF
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CANF stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
-28.43%
Can-Fite Biopharma shares are trading lower after ...
Unlock content with
Pro Subscription
5 months ago
-19.31%
Can-Fite Biopharma shares are trading lower. The company announced a Phase II design is completed and preparatory work is undergoing for the initiation of clinical study in the rare genetic disease Lowe Syndrome.
